相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
Ilaria S. Pagani et al.
LEUKEMIA (2020)
Prospects for achieving treatment-free remission in chronic myeloid leukaemia
Giuseppe Saglio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia
Tun Kiat Ko et al.
BLOOD (2020)
Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells
Yazad D. Irani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Targeting quiescent leukemic stem cells using second generation autophagy inhibitors
Pablo Baquero et al.
LEUKEMIA (2019)
Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib
Yllka Latifi et al.
BLOOD (2019)
Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia
Ramachandran Krishna Chandran et al.
GENE (2019)
Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells
Leyuan Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation
George M. Burslem et al.
CANCER RESEARCH (2019)
EMT Transition States during Tumor Progression and Metastasis
Ievgenia Pastushenko et al.
TRENDS IN CELL BIOLOGY (2019)
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
T. P. Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
Rebecca Mitchell et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
Rebecca Mitchell et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
Susan Branford et al.
BLOOD (2018)
PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia
Damian Lai et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
Laura N. Eadie et al.
Oncotarget (2018)
Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI
Puneet Agarwal et al.
BLOOD (2017)
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment
L. N. Eadie et al.
LEUKEMIA (2017)
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
M. Ilander et al.
LEUKEMIA (2017)
Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
Ami B. Patel et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
C. Schuetz et al.
LEUKEMIA (2017)
Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib
W. Qiang et al.
LEUKEMIA (2017)
Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
E. Hadzijusufovic et al.
LEUKEMIA (2017)
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
Andrew A. Wylie et al.
NATURE (2017)
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
Elodie M. Kuntz et al.
NATURE MEDICINE (2017)
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia
Alice Giustacchini et al.
NATURE MEDICINE (2017)
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
Amy Hughes et al.
FRONTIERS IN IMMUNOLOGY (2017)
Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34 +CD38- stem and progenitor cells in chronic myeloid leukemia
Monika Dolinska et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia
Yanli Jin et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H. Lipton et al.
LANCET ONCOLOGY (2016)
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
Sheela A. Abraham et al.
NATURE (2016)
Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
Mary T. Scott et al.
CANCER DISCOVERY (2016)
Chronic Myelogenous Leukemia-Initiating Cells Require Polycomb Group Protein EZH2
Huafeng Xie et al.
CANCER DISCOVERY (2016)
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV
Susanne Saussele et al.
BLOOD (2015)
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Javid J. Moslehi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
A. M. Eiring et al.
LEUKEMIA (2015)
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
Stephane Prost et al.
NATURE (2015)
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein
Anupriya Agarwal et al.
BLOOD (2014)
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
Paolo Gallipoli et al.
BLOOD (2014)
Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells
Claudio Raimondi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia
Leyuan Ma et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
Kimberly Cramer-Morales et al.
BLOOD (2013)
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling
Bin Zhang et al.
BLOOD (2013)
Regulation of c-Myc Ubiquitination Controls Chronic Myelogenous Leukemia Initiation and Progression
Linsey Reavie et al.
CANCER CELL (2013)
A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition
Daniel J. Goff et al.
CELL STEM CELL (2013)
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Paolo Neviani et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia
Qingfei Jiang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function
Sharon Lim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib
Ashu Kumari et al.
BLOOD (2012)
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice
Christoph Walz et al.
BLOOD (2012)
Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib
Ling Li et al.
CANCER CELL (2012)
Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML
Florian H. Heidel et al.
CELL STEM CELL (2012)
CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression
Christian Schuerch et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
E. Traer et al.
LEUKEMIA (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pushing the limits of targeted therapy in chronic myeloid leukaemia
Thomas O'Hare et al.
NATURE REVIEWS CANCER (2012)
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia
Nicola Esposito et al.
BLOOD (2011)
Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression
Claire M. Lucas et al.
BLOOD (2011)
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
Christian Hurtz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
Carlo Gambacorti-Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib
Shannon K. McWeeney et al.
BLOOD (2010)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Kazuhito Naka et al.
NATURE (2010)
Regulation of myeloid leukaemia by the cell-fate determinant Musashi
Takahiro Ito et al.
NATURE (2010)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells
Cristian Bellodi et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Chen Zhao et al.
NATURE (2009)
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
Yaoyu Chen et al.
NATURE GENETICS (2009)
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephanie Dulucq et al.
BLOOD (2008)
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells
Ji Wu et al.
BLOOD (2008)
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation
Christine Dierks et al.
CANCER CELL (2008)
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance
Nadine N. Bewry et al.
MOLECULAR CANCER THERAPEUTICS (2008)
PML targeting eradicates quiescent leukaemia-initiating cells
Keisuke Ito et al.
NATURE (2008)
Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo
Chen Zhao et al.
CANCER CELL (2007)
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2007)
Bcr-Abl stabilizes β-catenin in chronic myeloid leukemia through its tyrosine phosphorylation
Addolorata Maria Luce Coluccia et al.
EMBO JOURNAL (2007)
Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT 5 pathway activation
Ying Wang et al.
BLOOD (2007)
STAT5 signaling is required for the efficient induction and maintenance of CML in mice
Dan Ye et al.
BLOOD (2006)
Gene expression changes associated with progression and response in chronic myeloid leukemia
JP Radich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein
P Neviani et al.
CANCER CELL (2005)
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
CHM Jamieson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors
P Ramaraj et al.
CANCER RESEARCH (2004)
Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib
M Loriaux et al.
LEUKEMIA & LYMPHOMA (2004)
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
FX Mahon et al.
BLOOD (2003)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy
A Hochhaus et al.
LEUKEMIA (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
分享论文
